Johnson & Johnson announces completion of Novira Therapeutics, Inc. acquisition
Novira Therapeutics, Inc. is now part of the Infectious Diseases & Vaccines Therapeutic Area of the Janssen Pharmaceutical Companies of Johnson & Johnson. The acquisition includes Novira's portfolio of innovative antivirals, including its lead candidate, NVR 3-778 which is in Phase 1b clinical trials. NVR 3-778 is an investigational small molecule, direct-acting antiviral, for oral administration in patients with HBV that inhibits the HBV core or capsid protein. HBV core is a promising drug target since it is involved in multiple activities required for viral replication and persistence.
"We are exploring several approaches in pursuit of a functional cure for this insidious disease. Bringing together NVR 3-778 with our own internal discoveries we will leverage our vast experience in viral diseases to develop potentially transformational medicines for HBV patients," said William N. Hait, M.D., Ph.D., Global Head, Janssen Research & Development, LLC.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.